Insider Buy ·Filed Jun 18, 2026

PRTA

PROTHENA CORP PUBLIC LTD CO
BULLISH
Impact 5/10
Horizonweeks Processed3mo ago SEC0001045463-26-000009
Insider cluster: 1 insiders, $1.2M total
Actionable Insight ▲ Bullish

The 10% owner's open-market purchase is a positive signal, but PRTA's historical stock response to bullish calls has been poor (avg -4.55% at T+20). Watch for pipeline catalysts or earnings updates to confirm the insider's conviction. A small position relative to market cap limits immediate impact.

DirectionBullish
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
PRTA ▼ -0.78% at T+60d
LONG call ✗ call lost -0.78% · α vs SPY -2.68% · entry $8.93 → $8.86
Entry anchored
Jun 18, 11:38 AM ET
via exchange tick
T+1d
+2.46%
call +2.46% · α +2.78%
$9.15
settled 3mo ago
T+5d
+3.81%
call +3.81% · α +5.47%
$9.27
settled 3mo ago
T+20d
-5.15%
call -5.15% · α -5.68%
$8.47
settled 2mo ago
T+60d
-0.78%
call -0.78% · α -2.68%
$8.86
settled 17d ago

Price Chart

Loading chart...

Executive Summary

William P. Scully, a 10% owner of Prothena Corp, purchased $1.18M of PRTA shares in two open-market transactions at ~$8.10 per share. This conviction buy by a major insider signals confidence, though historical bullish calls on PRTA have underperformed.

Key Financial Metrics

Direction
buying
Total Value
$1.2M
Insiders
1

Key Facts

  • 10% owner William P. Scully bought 145,000 shares total for $1.18M
  • Purchases occurred on June 11 ($1.02M at $8.17) and June 16 ($158K at $7.90)
  • Total buy represents ~0.27% of PRTA's $444M market cap
  • Insider has been net buying over the past 30 days ($3.1M total)

Financial Impact

Insider purchase of $1.18M, modest relative to market cap

insider ownershipmarket confidence

Risk Factors

  • Historical bullish calls on PRTA have underperformed (40% win rate at T+20)
  • Purchase size is modest at 0.27% of market cap
  • Biotech sector risk with binary pipeline events

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (12 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
INSIDER-BUY Data (Synthetic)0001045463-26-000009
10 reports for PRTA
Performance horizon
50% Hit rate 2 of 4 directional calls best @ T+60▲ +14.11%Jun 12, 2026
Filters
Rows
Reports for PRTA — sortable, filterable
TypeNow
Sep 3, 2026
28d ago
Insider Buy
NEUTRAL ★ 3/10
$9.82 $8.86▼ −9.78%▼ −8.57%$8.44 (−14.05%)
Aug 21, 2026
6w ago
Insider Buy
BULLISH ★ 4/10
$9.45 $9.33▼ −1.27%▼ −1.74%$8.44 (−10.69%)
Aug 10, 2026
7w ago
Insider Buy
BULLISH ★ 5/10
$9.12 $8.88▼ −2.63%▼ −2.58%$8.44 (−7.46%)
Jul 31, 2026
9w ago
Insider Cluster
NEUTRAL ★ 2/10
$8.12 $8.76▲ +7.88%▲ +4.37%$8.44 (+3.94%)
Jun 18, 2026
15w ago
Insider Buy
BULLISH ★ 5/10
$8.93 $9.27▲ +3.81%▲ +5.47%$8.44 (−5.49%)
Jun 12, 2026
15w ago
Insider Buy
BULLISH ★ 5/10
$8.15 $9.15▲ +12.27%▲ +13.65%$8.44 (+3.56%)
May 14, 2026
20w ago
3
NEUTRAL ★ 2/10
$9.76 $9.83▲ +0.72%▼ −0.25%$8.44 (−13.52%)
May 7, 2026
21w ago
8-K
BULLISH ★ 8/10
$10.73 $9.86▼ −8.11%▼ −9.57%$8.44 (−21.34%)
Mar 27, 2026
26w ago
DEFA14A
NEUTRAL ★ 3/10
$9.25 $10.36▲ +12.00%▲ +7.70%$8.44 (−8.76%)
Mar 3, 2026
30w ago
EFFECT
NEUTRAL ★ 3/10
$9.36 $9.77▲ +4.38%▲ +4.86%$8.44 (−9.83%)
Showing 10 of 10

US Market Status

Market Open — Closes in 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access